SIRPA and cancer: Lipid-based NPs can increase anti-cancer efficacy by binding to SIPRα on macrophages and CD47 on cancer cells, at the same time as inhibiting CD47-SIRPα signalling pathway involved in the “do not eat me” signal (Ramesh et al., 2020).